Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1972 Jan;25(1):36–44. doi: 10.1136/jcp.25.1.36

The significance of variations in immunoreactive and clottable fibrinogen in health and following thrombosis

P Wolf 1,1, G W Farrell 1, K W Walton 1
PMCID: PMC477218  PMID: 4259368

Abstract

In individuals in a steady state of fibrinogen metabolism, immunoreactive and clottable fibrinogen estimates of plasma fibrinogen show close agreement. These estimates also detect any increase of plasma fibrinogen (due to increased synthesis) following metabolic stresses but in certain circumstances discrepancies between immunoreactive and clottable fibrinogen values occur which are of diagnostic assistance.

During extensive thrombosis, circulating `cryoprofibrin' (fibrin intermediates) may be formed. These fail to give full quantitative immunodiffusion reactions with antifibrinogen. Values for immunoreactive are therefore lower than for clottable fibrinogen.

When intravascular catabolism (due to plasmin action) accompanies increased synthesis, since some of the molecular breakdown products of fibrin or fibrinogen react with antifibrinogen but are not clottable, immunoreactive values exceed those for clottable fibrinogen. This discrepancy is therefore an indicator of thrombolysis.

Each discrepancy in turn may be encountered during the alternating predominance of thrombosis or thrombolysis in vivo: (a) physiologically, in association with the menstrual cycle; (b) pathologically, following surgical operations or extensive intravascular thrombosis.

Full text

PDF
36

Images in this article

40Image
on p.40
41Image
on p.41
42Image
on p.42

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALLISON A. C., HUMPHREY J. H. A theoretical and experimental analysis of double diffusion precipitin reactions in gels, and its application to characterization of antigens. Immunology. 1960 Jan;3:95–106. [PMC free article] [PubMed] [Google Scholar]
  2. BAILEY K., BETTELHEIM F. R. The clotting of fibrinogen. I. The liberation of peptide material. Biochim Biophys Acta. 1955 Dec;18(4):495–503. doi: 10.1016/0006-3002(55)90140-2. [DOI] [PubMed] [Google Scholar]
  3. Bennett N. B., Ogston C. M., Ogston D. Studies on the blood fibrinolytic enzyme system following acute myocardial infarction. Clin Sci. 1967 Feb;32(1):27–37. [PubMed] [Google Scholar]
  4. Blombäck B., Carlson L. A., Franzén S., Zetterqvist E. Turnover of 131-I-labelled fibrinogen in man. Studies in normal subjects, in congenital coagulation factor deficiency states, in liver cirrhosis, in polycythemia vera and in epidermolysis bullosa. Acta Med Scand. 1966 May;179(5):557–574. doi: 10.1111/j.0954-6820.1966.tb07973.x. [DOI] [PubMed] [Google Scholar]
  5. Davies J. W., Ricketts C. R., Bull J. P. Studies of plasma protein metabolism. 3. Fibrinogen in burned patients. Clin Sci. 1966 Apr;30(2):305–314. [PubMed] [Google Scholar]
  6. Farrell G. W., Wolf P. A simple method of preparing monospecific anti-human fibrin serum in rabbits. J Med Lab Technol. 1970 Jul;27(3):312–316. [PubMed] [Google Scholar]
  7. Farrell G. W., Wolf P. The measurement of fibrinogen and its derivatives. I. Examination of methods of measurement of clottable fibrinogen. Med Lab Technol. 1971 Jul;28(3):310–318. [PubMed] [Google Scholar]
  8. Fearnley G. R., Chakrabarti R. Fibrinolytic treatment of rheumatoid arthritis with phenformin plus ethyloestrenol. Lancet. 1966 Oct 8;2(7467):757–761. doi: 10.1016/s0140-6736(66)90360-6. [DOI] [PubMed] [Google Scholar]
  9. Kukral J. C., Zeineh R., Dobryszycka W., Pollitt J., Stone N. Metabolism of plasma proteins in injury states. I. Turnover rates of fibrinogen in burned patients labelled with [35S] methionine. Clin Sci. 1969 Apr;36(2):221–230. [PubMed] [Google Scholar]
  10. Lipinski B., Wegrzynowicz Z., Budzynski A. Z., Kopeć M., Latallo Z. S., Kowalski E. Soluble unclottable complexes formed in the presence of fibrinogen degradation products (FDP) during the fibrinogen-fibrin conversion and their potential significance in pathology. Thromb Diath Haemorrh. 1967 Feb 28;17(1-2):65–77. [PubMed] [Google Scholar]
  11. MCFARLANE A. S., TODD D., CROMWELL S. FIBRINOGEN CATABOLISM IN HUMANS. Clin Sci. 1964 Jun;26:415–420. [PubMed] [Google Scholar]
  12. Merskey C., Kleiner G. J., Johnson A. J. Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment. Blood. 1966 Jul;28(1):1–18. [PubMed] [Google Scholar]
  13. NUSSENZWEIG V., SELIGMANN M., GRABAR P. [The degradation products of human fibrinogen by plasmin. II. Immunological study: existence of native anti-fibrinogen antibodies possessing different specificities]. Ann Inst Pasteur (Paris) 1961 Apr;100:490–508. [PubMed] [Google Scholar]
  14. REGOECZI E., REGOECZI G. E., MCFARLANE A. S. RELATION BETWEEN RATE OF CATABOLISM, PLASMA CONCENTRATION AND POOL SIZE OF FIBRINOGEN. Pflugers Arch Gesamte Physiol Menschen Tiere. 1964 Mar 12;279:17–25. doi: 10.1007/BF00363316. [DOI] [PubMed] [Google Scholar]
  15. SHAINOFF J. R., PAGE I. H. Significance of cryoprofibrin in fibrinogen-fibrin conversion. J Exp Med. 1962 Nov 1;116:687–707. doi: 10.1084/jem.116.5.687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Takeda Y. Studies of the metabolism and distribution of fibrinogen in healthy men with autologous 125-I-labeled fibrinogen. J Clin Invest. 1966 Jan;45(1):103–111. doi: 10.1172/JCI105314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. WOLF P., WALTON K. W. INVESTIGATION OF A QUANTITATIVE ANOMALY ENCOUNTERED IN THE ASSAY OF FIBRINOGEN BY IMMUNO-DIFFUSION. Immunology. 1965 Jan;8:6–24. [PMC free article] [PubMed] [Google Scholar]
  18. Werner M., Cohnen G. Changes in serum proteins in the immediate postoperative period. Clin Sci. 1969 Apr;36(2):173–184. [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES